Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | LTA4H | P09960 | 4/20 | 0.66 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.66 |
| ▸ | HTR1D | P28221 | 6/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.60 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 3/20 | 0.57 |
| ▸ | HTR1B | P28222 | 3/20 | 0.57 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | NSD2 | O96028 | 1/20 | 0.53 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273357 | 0.90 | IMPDH2 (0.69) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL29007183 | 0.85 | TRPM8 (0.76) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL29617411 | 0.85 | TRPM8 (0.76) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL24183187 | 0.84 | TRPM8 (0.74) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL8868782 | 0.83 | TRPM8 (0.65) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL28100769 | 0.83 | TRPM8 (0.72) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL2007192 | 0.83 | TRPM8 (0.72) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL5857843 | 0.82 | IMPDH2 (0.81) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| 5-Benzyloxytryptamine SCHEMBL29785061 | 0.81 | TRPM8 (1.00) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL6988545 | 0.81 | HTR1D (0.78) | TRPM8KDM4EMAPTLTA4HPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1239482-C | Positive modulators for nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2006-02-01 | — | — | CN | claimed |
| US-6750242-B1 | Positive modulators of nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | claimed |
| CN-1387512-A | Positive modulators of nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2002-12-25 | — | — | CN | claimed |
| EP-1230216-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-08-14 | — | — | EP | claimed |
| WO-2001032619-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | claimed |
| US-20220390454-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | ARTEREZ, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2021062298-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | ARTEREZ, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| EP-3307724-B1 | (Z)-2-(1H-INDOL-3-YL)-3-(ISOQUINOLIN-5-YL)ACRYLONITRILE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOSOME INHIBITORY AND ANTI-MITOTIC ACTIVITY FOR TREATING HYPERPROLIFERATIVE DISEASES | NAT UNIV SINGAPORE (SG) | 2020-06-10 | — | — | EP | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-10308631-B2 | Selective anti-cancer compounds | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2019-06-04 | — | — | US | disclosed |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2018-06-28 | — | — | US | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-6750242-B1 | Positive modulators of nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2004-06-15 | — | — | US | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| CN-1387512-A | Positive modulators of nicotinic receptor agonists | ASTRAZENECA AB (SE) | 2002-12-25 | — | — | CN | disclosed |
| EP-1230216-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032619-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308631-B2 | Selective anti-cancer compounds | CCNA1, CCNY, CCNT1 | TRPM8 4750/4885KDM4E 892/4885MAPT 4410/4885 |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | TRPM8 376/4885KDM4E 4534/4885MAPT 2587/4885 |
| US-20180179178-A1 | SELECTIVE ANTI-CANCER COMPOUNDS | CCNA1, CCNY, CCNT1 | TRPM8 4750/4885KDM4E 892/4885MAPT 4410/4885 |
| US-20220390454-A1 | BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION | SDCBP, LGALS2, SDC1 | TRPM8 3530/4885KDM4E 3995/4885MAPT 1840/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | TRPM8 251/4885KDM4E 4581/4885MAPT 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.